• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
February 15, 2017 07:59 AM ESTUpdated February 27, 12:49 PM
Startups

Sur­rozen grabs $33M, joins star­tups look­ing to spark a come­back in re­gen­er­a­tive med

John Carroll

Editor & Founder

In an­oth­er sign that the long, cold win­ter for re­gen­er­a­tive med­i­cine may be com­ing to an end, The Col­umn Group led a $33 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • As re­searchers come to­geth­er for HIV con­fer­ence, few biotechs can stay the course July 11, 2025
  • Watch Post-Hoc Live: Is Chi­na a threat or in­vest­ment op­por­tu­ni­ty for the US? July 10, 2025
  • Kid­ney health biotech emerges with $54M to fol­low in Ver­tex’s foot­steps July 10, 2025
TRENDING NOW

Af­ter Phase 3 obe­si­ty suc­cess, Hen­grui plans Chi­na ap­proval fil­ing for Kail­era-part­nered drug

FDA em­ploy­ees let go in April re­ceive fi­nal ter­mi­na­tion no­tices

FDA chief calls for low­er user fees as ne­go­ti­a­tions be­gin for eighth round of PDU­FA

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Af­ter long saga, 23and­Me's deal with Anne Wo­j­ci­ck­i's non­prof­it fi­nal­ly clos­es

WHO adds Gilead­'s twice-year­ly in­jec­tion to glob­al PrEP guide­lines

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times